Ironwood Pharmaceuticals, Inc. revised earnings guidance for its Fiscal Year 2024. Total Revenue reported its Prior 2024 Guidance of $435 to $455 million as compared to Revised 2024 Guidance of revenue to be $405 to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.58 USD | -2.11% |
|
-6.69% | -51.22% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.22% | 887M | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+34.49% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024